Head-to-Head Comparison

Semaglutide vs Tirzepatide

The two most researched GLP-1 agonists for metabolic and weight management. One targets GLP-1 alone, the other hits both GLP-1 and GIP. Here’s how they compare.

	Semaglutide	Tirzepatide
Class	GLP-1 Receptor Agonist	Dual GIP/GLP-1 Receptor Agonist
Developer	Novo Nordisk	Eli Lilly
Brand Names	Ozempic, Wegovy, Rybelsus	Mounjaro, Zepbound
Receptors	GLP-1 only	GLP-1 + GIP (dual)
Route	SubQ (oral form exists)	SubQ only
Half-Life	~7 days	~5 days
Frequency	Once weekly	Once weekly
Starting Dose	0.25 mg	2.5 mg
Max Dose	2.4 mg	15 mg
Escalation	5 steps over 16+ weeks	5 steps over 16+ weeks
Avg Weight Loss	~15–17% body weight (68 wks)	~20–22.5% body weight (72 wks)
CV Data	SELECT trial: 20% MACE reduction	CV outcome trials ongoing
GI Side Effects	Nausea, vomiting common early	Similar or slightly lower nausea rates

When to Use Each

Choose Semaglutide When

Cardiovascular risk reduction is a priority (proven SELECT trial data)
An oral option is needed (Rybelsus)
Longer half-life is preferred for stable blood levels
More long-term safety data matters to you (earlier to market)
Budget is a factor (more generic/compounded options available)
Moderate weight loss goal (10–17% body weight)

Choose Tirzepatide When

Maximum weight reduction is the primary goal (20%+ body weight)
Dual receptor activation (GIP + GLP-1) is the research focus
GI tolerability is a concern (may cause less nausea)
Prior GLP-1 monotherapy produced insufficient results
Insulin sensitivity improvement is a key objective
Aggressive metabolic research protocol is planned

⚠ Do Not Stack These Together. Semaglutide and tirzepatide both act on the GLP-1 receptor. Combining them significantly increases the risk of severe GI side effects, pancreatitis, and hypoglycemia. Choose one based on your research objectives. They are not complementary – they are alternatives.

The Bottom Line

Semaglutide is the more established compound with proven cardiovascular benefits and the most long-term safety data. It’s the conservative choice with strong clinical backing and an oral option.

Tirzepatide is the newer, potentially more potent option. Its dual GIP/GLP-1 mechanism has produced the largest weight reductions seen in clinical trials, but it has less long-term safety data and no completed CV outcomes trial yet.

Both require slow dose escalation, both cause GI side effects early on, and both show significant weight regain after discontinuation. The best choice depends on your specific research goals, tolerability, and how much long-term data matters to your protocol.

Read the Full Guides

Semaglutide

Mechanisms, dosing protocol, FAQ, and sourcing.

Full Semaglutide Guide →

Tirzepatide